MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Large Decrease in Short Interest

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totalling 622,500 shares, a decline of 15.6% from the March 31st total of 737,400 shares. Approximately 2.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 219,600 shares, the days-to-cover ratio is presently 2.8 days.

Institutional Trading of MAIA Biotechnology

A hedge fund recently raised its stake in MAIA Biotechnology stock. Geode Capital Management LLC grew its stake in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) by 22.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 192,563 shares of the company's stock after purchasing an additional 35,821 shares during the period. Geode Capital Management LLC owned approximately 0.76% of MAIA Biotechnology worth $541,000 at the end of the most recent reporting period. 5.65% of the stock is owned by institutional investors.

MAIA Biotechnology Stock Performance

Shares of MAIA traded up $0.15 during midday trading on Tuesday, hitting $2.06. 424,447 shares of the company traded hands, compared to its average volume of 236,830. The stock has a market cap of $53.89 million, a price-to-earnings ratio of -1.49 and a beta of 0.20. The firm has a 50 day moving average of $1.72 and a 200-day moving average of $2.14. MAIA Biotechnology has a 52 week low of $1.40 and a 52 week high of $5.99.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.